Biovica International AB (publ) (BIOVICB) Earnings Call Transcripts

Biovica International AB (publ)'s Latest Earnings Call - Q4 FY2026

In Q4 of fiscal year 2025-2026, Biovica International AB reported sales of SEK 4.8 million, marking a significant increase driven by its Pharma Services segment. Full-year sales reached SEK 13.4 million, reflecting a 55% growth year-over-year in Swedish krona and a 74% increase in local currency. The company has shifted its strategic focus away from European markets, which it does not expect to generate revenue from in the near term, while emphasizing growth in the U.S. market, particularly in hormone receptor-positive metastatic breast cancer. Management signaled a commitment to reducing cash burn and extending the company's runway, which could enhance investor confidence moving forward.

Reported metrics

Guidance from management

Management indicated a commitment to reducing cash burn and extending the company's runway, with expectations for continued growth in the Pharma Services segment. However, no specific revenue guidance was provided for the upcoming fiscal year.

What management said

While I will remain being a little bit cautious considering this is still my week 7 with the company, so early and in my listening mode, it is a clear signal that we will continue to see a robust growth from the Pharma business. But unfortunately, I'm not able to give you more guidance than naturally, this is a business we continue to see growing and will also continue to grow this fiscal year over the past fiscal ye...

I would -- there's a lot of assumptions we have to put and make here. But if we do assume that this is essentially helping identify the right patients, then I would personally and subjectively be confident in believing that it will also lead to CDx collaborations.

What analysts pressed on

Analysts expressed concerns about the slow adoption of IVD sales in the U.S. and the lack of revenue generation in Europe. There were also questions regarding the timeline for achieving significant milestones in clinical adoption and companion diagnostics.

Main topics on the call

• Strong Revenue Growth — Biovica reported Q4 sales of SEK 4.8 million, driven by an 18% increase in U.S. IVD sales and significant growth in Pharma Services. CFO Anders Moren noted, "April was our strongest month to date," indicating ongoing mom...
• Shift in Strategic Focus — Management has decided to halt efforts for European IVDR certification, stating, "We have not generated sales in Europe during the past fiscal year," and will focus solely on the U.S. market for the foreseeable future.
• Pharma Services Growth — The Pharma Services segment has seen substantial growth, with ongoing contract value nearly doubling to SEK 23 million. Theis Kipling remarked, "This is a business we continue to see growing and will also continue to gro...
• Cash Position and Cost Management — Biovica ended the quarter with SEK 70.4 million in cash and is implementing tighter cost controls. Moren stated, "We expect slightly lower costs in the next 12 months compared to the SEK 84 million that we had in the fis...

Read the full Biovica International AB (publ) transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 27 Biovica International AB (publ) earnings call transcripts on record, spanning March 12, 2020 to June 17, 2026. Based on this history, Biovica International AB (publ) reports quarterly. The most recent call on file is dated June 17, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BIOVICB

Exchange

OM

Country

SE

Sector

Health Care

Industry

Biotechnology

Calls on record

27

First call

March 12, 2020

Most recent

June 17, 2026

Reporting cadence

quarterly